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Cost-Effectiveness Analysis of Smoking Cessation Interventions in the
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Edna Keeney, MSc, Nicky J. Welton, PhD, Matt Stevenson, PhD, Michael N. Dalili, PhD, José A. López-López, PhD,
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A B S T R A C T
Objectives: Smoking is a leading cause of death worldwide. Cessation aids include varenicline, bupropion, nicotine replace-
ment therapy (NRT), and e-cigarettes at various doses (low, standard and high) and used alone or in combination with each
other. Previous cost-effectiveness analyses have not fully accounted for adverse effects nor compared all cessation aids. The
objective was to determine the relative cost-effectiveness of cessation aids in the United Kingdom.
Methods: An established Markov cohort model was adapted to incorporate health outcomes and costs due to depression and
self-harm associated with cessation aids, alongside other health events. Relative efficacy in terms of abstinence and major
adverse neuropsychiatric events was informed by a systematic review and network meta-analysis. Base case results are
reported for UK-licensed interventions only. Two sensitivity analyses are reported, one including unlicensed interventions
and another comparing all cessation aids but removing the impact of depression and self-harm. The sensitivity of
conclusions to model inputs was assessed by calculating the expected value of partial perfect information.
Results: When limited to UK-licensed interventions, varenicline standard-dose and NRT standard-dose were most cost-
effective. Including unlicensed interventions, e-cigarette low-dose appeared most cost-effective followed by varenicline
standard-dose 1 bupropion standard-dose combined. When the impact of depression and self-harm was excluded,
varenicline standard-dose 1 NRT standard-dose was most cost-effective, followed by varenicline low-dose 1 NRT
standard-dose.
Conclusion: Although found to be most cost-effective, combined therapy is currently unlicensed in the United Kingdom and
the safety of e-cigarettes remains uncertain. The value-of-information analysis suggested researchers should continue to
investigate the long-term effectiveness and safety outcomes of e-cigarettes in studies with active comparators.
Keywords: cost-effectiveness, economic model, smoking cessation, value of information.
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Introduction
Cigarette smoking is one of the leading causes of early death in
the United Kingdom and worldwide.1,2 Although smoking is now
down to fewer than 1 in 6 adults (14%) in the United Kingdom, this
still equates to approximately 7.35 million people in the popula-
tion.3 In 2017, 16% of all deaths were attributed to smoking, and
33% of deaths for conditions that can be caused by smoking.3 The
cost of smoking to the UK National Health Service (NHS) has been
estimated at between approximately £2.6 and £5 billion a year,4,5
with the total cost to society in England estimated at approxi-
mately £12.9 billion a year.6
National Institute for Health and Care Excellence (NICE) public
health guidance recommends the use of three medicines: vare-
nicline, bupropion, and nicotine replacement therapy (NRT), as
aids to quitting smoking in the United Kingdom.7 These medicines
can be used at different doses and alone or in combination.
Although combinations are used, they are not licensed. E-ciga-
rettes are also currently not licensed in the United Kingdom,
although there were an estimated 3.2 million adult users in Great
Britain in 2018.8
Concerns have been raised about the safety of some smoking
cessation medicines, particularly the neuropsychiatric safety of
varenicline and buproprion. Severe safety warnings regarding a
potential increased risk of neuropsychiatric adverse events
(depression, suicidal ideation, and suicidal behavior) in patients
prescribed varenicline have previously been issued by regulatory
agencies.9,10 These safety warnings were removed in 201611,12
following the results of a large US trial (EAGLES),13 which did
not show a significant increase in neuropsychiatric adverse events
attributable to varenicline or bupropion relative to nicotine patch
or placebo. The language describing serious mental health side
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effects seen in patients quitting smoking was also removed from
the bupropion label.12 However concerns have since been raised
that the study was under-powered to detect a rare adverse effect
such as suicide.14 It is therefore important to include the conse-
quences of neuropsychiatric safety on costs and quality of life in an
economic evaluation of medicines for smoking cessation.
We use efficacy and safety results from a recent network meta-
analysis (NMA) to provide an updated cost-effectiveness analysis
of smoking cessation medicines in a UK setting. Our results help to
inform the overall risk-benefit evaluation of the different medi-
cines and determine which intervention, or combination of in-
terventions, represents the best “value for money” to the NHS.
Unlike previous studies, we compare a range of licensed and un-
licensed interventions, and the impact of neuropsychiatric adverse
events is incorporated. This will allow patients, prescribers, and
regulators to make more informed decisions about intervention
choice.
Methods
The population considered in the decision were smokers in the
United Kingdom aged 18 years or over. The interventions
compared in the base case were those currently licensed in the
United Kingdom: NRT at low, standard, and high dose; bupropion
at low and standard dose and varenicline at low and standard
dose. As e-cigarettes and combination interventions are not
currently licensed as smoking cessation interventions in the
United Kingdom, we exclude these in the base-case but include
them in a sensitivity analysis. E-cigarettes at low and high dose
and the following combinations of interventions were considered
in the sensitivity analysis, alongside the licensed interventions:
bupropion standard dose1 NRT high dose; varenicline low dose1
NRT standard dose; varenicline standard dose 1 NRT standard
dose; varenicline standard dose 1 NRT high dose; and varenicline
standard 1 bupropion standard dose.
Standard practice in the NHS is to offer NRT to smokers
attempting to quit, at a dose based on level of cigarette use,
including combinations of NRT modes of delivery (for example
patch and gum). We therefore use NRT standard dose as the
reference intervention for comparison in the cost-effectiveness
analysis. The perspective taken is that of the UK NHS for costs
and health effects of the individual for outcomes, in line with NICE
guidance.15 A lifetime time horizon was taken to predict costs and
health effects over a participant’s lifetime.
The model structure is based on the Sheffield model by Leaviss
and colleagues16 used in a 2014 Health Technology Assessment
report on the clinical and cost-effectiveness of cytisine compared
with varenicline for smoking cessation. This in turn was based on
the Benefits of Smoking Cessation on Outcomes (BENESCO)
model,17 a widely used cost-effectiveness model, which has pre-
viously been applied to model the effects of smoking cessation
interventions in the United Kingdom, the United States, Germany,
France, Belgium, the Netherlands, Finland, Sweden, and South
Korea.18–27
The model simulates a cohort of smokers making a quit
attempt over time, tracking morbidity and mortality to calculate
the costs and benefits associated with different smoking cessation
aids. Both the cost of the intervention and costs and health state
disutilities associated with the smoking-related illnesses of
chronic obstructive pulmonary disease, lung cancer, coronary
heart disease, stroke, and asthma are captured. The prevalence,
incidence, and mortality from these events are considered to
depend on whether a person is a smoker, recent quitter, or
long-term quitter, as well as their age and sex. Cohort members
accumulate costs and health outcomes each cycle until death.
Future costs and benefits are discounted at a rate of 3.5% per
annum.15
No previous model or variation of the BENESCO model has
considered adverse events associated with the interventions
themselves. We have incorporated these as a probability of
experiencing depression or fatal/nonfatal self-harm in the first
year of the intervention. Depression and nonfatal self-harm are
represented by a one-off disutility and cost whereas fatal self-
harm also results in death. We remove the impact of depression




The probability of smoking cessation associated with NRT was
estimated from Taylor et al (2017).28 Taylor et al published a
prospective cohort study of electronic medical records from 149
526 patients who were prescribed NRT. At 1 year, 21.2% (695 of
149 526) of those prescribed NRT quit. The probabilities of
cessation at one year for the other interventions were then ob-
tained by applying the relative effects estimated in a NMA on
sustained abstinence29 to the cessation probabilities for NRT. The
mean probabilities of 1-year sustained abstinence for all
interventions used in the model are shown Appendix Table 1 in
the Supplementary Material found at https://doi.org/10.1016/
j.jval.2020.12.012 and suggest that varenicline low 1 NRT stan-
dard and varenicline standard 1 NRT standard have the highest
probability of sustained abstinence (44%, 95% Credible Interval
(CrI) 0.17-0.74 and 44%, 95% CrI 0.23-0.67, at 1 year, respectively)
followed by e-cigarettes at low dose (32%, 95% CrI 0.12-0.63).
The probabilities of depression and self-harm at 1 year asso-
ciated with NRT standard were estimated from Kotz et al.30 This
was a retrospective cohort study of 106 759 patients who were
prescribed NRT. Of these, 8274 reported having depression giving
a probability of 7% and 540 reported self-harm giving a probability
of 0.5%. The probabilities of depression and self-harm associated
with the other interventions were generated applying the relative
effects estimated in a NMA on major adverse neuropsychiatric
events (MANE)29 to the probabilities of depression and self-harm
on NRT. The mean probabilities of depression and self-harm for all
interventions used in the model are also shown in Appendix
Table 1 in the Supplementary Material found at https://doi.org/
10.1016/j.jval.2020.12.012.
Because no data were available in the NMA on MANE
(depression and self-harm) for some interventions, assumptions
had to made about their relative level of harm. We assumed that
NRT low and e-cigarette low have the same level of harm as NRT
standard. Similarly, e-cigarette high was assumed to have the
same level of harm as NRT high. In addition, bupropion low was
assumed to have the same level of harm as bupropion standard
and varenicline low 1 NRT standard the same level of harm as
varenicline standard 1 NRT standard. The assumption that NRT
and e-cigarettes have the same impact on psychological outcomes
was believed to be reasonable as the active ingredient is the same
in both (nicotine). Although a higher dose of bupropion or vare-
nicline may increase the probability of depression or self-harm, no
evidence was available to inform this.
The relative effects of abstinence, depression and self-harm
were estimated using Bayesian NMA, computed using Markov
chain Monte Carlo simulation in OpenBUGS.31 Simulated samples
for the model were drawn from 60 000 Markov chain Monte Carlo
samples from the posterior distributions (following 50 000 burn-
in samples after which convergence was deemed satisfactory).29
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Prevalence, Incidence, and Mortality Associated With
Smoking-Related Diseases
The distribution of the cohort across sex and age categories at
the start of the model was designed to reflect the distribution of
smokers in the United Kingdom. The proportion of male and fe-
male adults and mortality risk in each of the 3 age categories (18-
34, 35-64, and 651 years old) was determined from general
population data.32,33 Smoking prevalence data34 were applied to
these data to calculate the distribution across age and sex groups
for a representative sample of 10,000 UK smokers (Appendix
Table 2 in the Supplementary Material found at https://doi.org/
10.1016/j.jval.2020.12.012).
The prevalence, incidence and mortality from smoking-related
diseases in the smoking cohort was estimated based on various
literature sourcesongeneralUKpopulationfigures and risk ratios of
these diseases in smokers, recent quitters, and long-run quitters
(Appendix Tables 2 and 3 in the Supplementary Material found at
https://doi.org/10.1016/j.jval.2020.12.012). Relative risks for the
prevalence of each disease in smokers relative to never-smokers
were taken from the Statistics on Smoking England 2017 report35
for chronic obstructive pulmonary disease, lung cancer, coronary
heart disease, and stroke, and Cassino et al36 for asthma (Appendix
Table 4 in the Supplementary Material found at https://doi.org/10.
1016/j.jval.2020.12.012).
Relapse Rates
Hawkins et al37 used British Household Panel Survey data to
look at smokers who quit but later relapsed. These data were used
to calculate the annual relapse probability for short-run quitters
(people for whom it had been less than 5 years since they quit;
0.13, 95% CrI 0.12-0.14) and long-run quitters (people who had quit
smoking for .5 years but ,10 years; 0.03, 95% CrI 0.02-0.05). The
annual relapse probability $10 years post cessation (0.0009, 95%
CrI 0.0004-0.0015) was based on a study by Krall and colleagues
which followed 483 men for up to 35 years.38
Costs and Utilities
Costs and utilities are accumulated in the model by following a
cohort of quitters moving between different health states. Esti-
mates for the costs associated with health states came from a
range of data sources including a recent report by the Irish Health
Information Quality Authority,39 the British Heart Foundation’s
CVD statistics40 and recent UK articles41,42 (Appendix Table 5 in
the Supplementary Material found at https://doi.org/10.1016/j.
jval.2020.12.012). Uncertainty around cost estimates was incor-
porated into the probabilistic analysis. These data were assumed
to follow a gamma distribution.43 A one-off cost was also associ-
ated with the initial smoking cessation intervention received.
Costs for all interventions including combinations of interventions
were based on estimates from the British National Formulary and
are shown in Appendix Table 5 in the Supplementary Material
found at https://doi.org/10.1016/j.jval.2020.12.012. All costs were
inflated to 2019 prices using HM Revenues Monthly Exchange
rates for February 2019.44
Baseline utility for smokers with no current comorbidity was
taken from the general population utility profile estimated by Ara
and Brazier using 2003 and 2006 Health Survey for England
data.45 Disease-specific utility values for smoking-related diseases
were estimated from the literature.42,45–51 Choice of estimates was
based on sample size and relevance to a contemporary UK pop-
ulation. The estimates are shown in Appendix Table 5 in the
Supplementary Material found at https://doi.org/10.1016/j.jval.202
0.12.012.
How Results Are Reported
We conduct a probabilistic analysis where uncertainty in the
model inputs is captured by simulating 5000 times from the
assumed distributions of the parameters described in the previous
section, using Monte Carlo simulation performed in Excel version
1908 (Microsoft Corporation, Redmond, WA). We report mean
lifetime costs and quality adjusted life years (QALYs) for each
intervention. Incremental cost-effectiveness ratios (ICERs), which
are the ratio of the incremental costs and incremental QALYs, are
reported for all interventions compared with NRT low. An inter-
vention is considered to be dominated if it provides less mean
QALYs at a higher mean cost than another intervention, and ex-
tendedly dominated if it provides less mean QALYs at a higher
mean cost than a weighted average of 2 alternative interventions.
We also report the expected net benefit with 95% confidence
interval for all interventions, where expected net benefit = mean
QALYs 3 WTP – mean costs, where WTP is the willingness-to-pay
threshold. A WTP threshold of £20 000 is chosen as this is the
lower threshold referred to in the NICE reference case.52
Cost-effectiveness acceptability curves (CEACs) are plotted
alongside rank-o-grams. CEACs plot the probability that each
intervention is the most cost-effective (highest NB). Rank-o-grams
show the distribution of the probabilities that each intervention is
most cost-effective, second most cost-effective, third most cost-
effective, and so on for each of the 14 interventions, at a fixed
willingness to pay threshold, in this case £20 000 per QALY.53 The
x-axis reports each of the possible ranks, for which position 1
means that the intervention is most cost-effective. The y-axis
shows the probability that each intervention has been ranked at
each of the possible positions and therefore fully encapsulates the
uncertainty in the intervention rankings. We also report the me-
dian rank and interquartile range for each intervention.
We explore how uncertainty in the model inputs impacts on
the intervention considered to be optimal using value of infor-
mation (VoI) methods.54 The expected value of perfect informa-
tion (EVPI) and expected value of partially perfect information
(EVPPI) give an upper bound on the benefit in reducing uncer-
tainty in all or a subset of the model inputs, respectively. EVPPI can
be used to identify which parameters the decision is most sensi-
tive to. EVPI and EVPPI are computed per person for a willingness-
to-pay per QALY threshold of £20 000 and multiplied by the
estimated number of smokers attempting to quit in England of 274
0213 to obtain population-level EVPI and EVPPI. The Sheffield
Accelerated Value of Information web application55 was used to
compute EVPPI for subsets of parameters.56
Finally, we present 2 sensitivity analyses. One expanding the
analysis to include e-cigarettes and combinations of interventions
and another where the impacts of depression and self-harm in the
model are removed, so the results are driven by abstinence from
smoking alone.
Results
Table 1 shows the primary results of the base case analysis: per
smoker expected total discounted costs and QALYs for all UK-
licensed interventions during over the simulation sample in a
probabilistic analysis. Interventions are ordered by increasing
expected total cost with NRT low having the lowest expected total
cost, and varenicline low having the highest expected total cost.
Varenicline standard has the highest expected QALYs followed by
NRT standard. NRT low has the lowest expected QALYs.
All interventions are dominated by varenicline standard apart
from NRT low and NRT standard. Bupropion low is extendedly
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dominated by NRT standard as its ICER is higher than that of NRT
standard, the next most effective alternative. If the decision maker
is only willing to pay up to £32 per QALY, NRT low would be
considered the most cost-effective intervention. At any willing-
ness to pay value between £32 and £15 665, NRT standard is most
cost-effective and at a willingness to pay value above £15 665,
varenicline standard is most cost effective. Varenicline standard
has the highest expected net benefit (£3697), followed by NRT
standard (£3663).
We present the uncertainty surrounding the cost-effectiveness
of the various interventions, using a CEAC. Figure 1 shows that at
any willingness-to-pay value above £100, NRT standard has the
highest probability of being cost-effective, followed by varenicline
standard. At any threshold above £20 000 the probability of NRT
standard being the most cost-effective intervention is never more
than 50%, indicating a degree of uncertainty in the optimal
intervention.
The rank-o-grams presented in Figure 2 and median ranks in
Table 1 show that both NRT standard and varenicline standard
have a high probability of being among the most cost-effective
interventions. Conversely, varenicline low and NRT low show
higher probabilities of being among the lowest ranking
interventions.
Value-of-Information Analysis
Table 2 shows the results of the VoI analyses for the base-case
model at a willingness to-pay per QALY threshold of £20 000. The
per-quitter EVPI is £708 and the population EVPI, representing all
of the smokers attempting to quit in England, is £194 million for a
1-year time horizon and £971 million for a 5-year time horizon.
These values are substantial and suggest that future research
studies to reduce parameter uncertainty in the model would be
valuable as the decision is clearly sensitive to uncertainty in the
model inputs. There is a high value per smoker in reducing un-
certainty in all of the abstinence probabilities (£473) but more
value in reducing uncertainty in all of the adverse events proba-
bilities (£575). EVPPI is lower for cost parameters (£58) than for
utility parameters (£118).
We explored the EVPPI of a new trial comparing the 2 in-
terventions with the highest expected net benefit, NRT standard
and varenicline standard, which would provide information on
the effectiveness of the interventions, costs, and utilities. This
gives a per-quitter EVPPI of £544 and a population EVPPI of £149
million for a 1-year time horizon and £746 million for a 5-year
time horizon. Restricting to the collection of intervention effects
only reduces this value marginally to £528 per quitter, suggesting
Table 1. Expected total costs, expected total utilities, ICERs, and expected net benefit at a £20 000 willingness-to-pay threshold based
on UK licensed interventions only.
Intervention Total costs Total QALYs ICER ENB (95% CI) (£) Median rank (IQR)
NRT low £10 259 10.934 0 7 (6-7)
Bupropion low £10 283 11.038 Extendedly dominated 2056 (2010, 2102) 5 (4-6)
NRT STD £10 292 11.119 £32 3663 (3617, 3710) 2 (1-3)
Bupropion STD £10 304 11.033 Dominated 1937 (1902, 1971) 5 (4-5)
NRT high £10 309 11.092 Dominated 3092 (3053, 3131) 3 (2-4)
Varenicline STD £10 413 11.127 £15 665 3697 (3659, 3734) 2 (1-3)
Varenicline low £10 440 10.959 Dominated 308 (211, 405) 6 (4-7)
CI indicates confidence interval; ENB, expected net benefit; ICER, Incremental cost-effectiveness ratios; IQR, interquartile range; NRT, nicotine replacement therapy;
QALY, quality adjusted life years; STD, standard.
Figure 1. CEAC. Probability treatment is optimal plotted against different willingness-to-pay per unit increase in utility (ceiling ratio).
Based on 5000 Monte Carlo simulations.
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that it is most important to collect information on probabilities of
abstinence and adverse events.
Sensitivity Analyses
Table 3 shows the primary results of the sensitivity analysis
where all licensed and unlicensed interventions are compared. In
this case all interventions apart from NRT low are dominated by e-
cigarette low, which is more effective, in terms of increased QALYs,
and less expensive than the other interventions. At a willingness-
to-pay threshold of £20 000, e-cigarette low has the highest
expected net benefit (£7085), followed by varenicline standard 1
bupropion standard (£6756), and varenicline standard 1 NRT
standard (£6591).
The median ranks and rank-o-grams presented in Appendix
Table 3 and Figure 1 of the Supplementary Material found at
https://doi.org/10.1016/j.jval.2020.12.012 demonstrate the uncer-
tainty in these results. In the rank-o-grams the lines are relatively
flat for most interventions showing that there is no strong prob-
ability that any will be most or least cost-effective at a £20 000 per
QALY threshold. The exception is NRT low which shows a high
probability of being among the least cost-effective interventions.
There is a similar trend for bupropion low, bupropion standard,
and varenicline low. The reverse trend is seen for e-cigarette low,
Figure 2. Rank-o-grams showing the probability that each intervention is ranked 1st, 2nd,. etc. based on Net Benefit at a willingness








































































































1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7 1 2 3 4 5 6 7
1 2 3 4 5 6 71 2 3 4 5 6 7
Table 2. Expected value of perfect information and EVPPI for various subsets of model parameters, at a £20,000 willingness-to-pay
value per QALY.
Model parameter subsets EVPPI per smoker





All (EVPI) 709 194 971
All costs 58 16 79
All utilities 118 32 161
All costs and utilities 403 110 552
All abstinence probabilities 473 130 648
All depression and self-harm probabilities 575 157 787
NRT STD vs varenicline STD (probabilities, costs and utilities) 544 149 745
NRT STD vs varenicline STD (probabilities only) 528 145 723
EVPPI indicates expected value of partially perfect information; NRT, nicotine replacement therapy; QALY, quality adjusted life years; STD, xxxx.
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varenicline low 1 NRT standard, varenicline standard 1 NRT
standard and varenicline standard 1 bupropion standard, which
all have the highest median rank of 3.
The VoI results based on this analysis are shown Appendix
Table 8 of the Supplementary Material found at https://doi.org/
10.1016/j.jval.2020.12.012. We again explored the EVPPI of a new
trial comparing the two interventions with the highest expected
net benefit, e-cigarette low and varenicline standard 1 bupropion
standard. This gives a per-quitter EVPPI of £2342 and a population
EVPPI of £642 million for a 1-year time horizon and £3209 million
for a 5-year time horizon. Restricting to the collection of inter-
vention effects only reduces this value marginally to £1676 per
quitter, suggesting that a trial comparing e-cigarettes low to an
active comparator such as varenicline standard 1 bupropion
standard or NRT standard is likely to be a cost-effective
investment.
Table 4 shows the primary results of the sensitivity analysis
where all interventions are compared but the impact of depres-
sion and self-harm is removed from the model. In this case,
e-cigarette low is replaced by varenicline standard 1 NRT stan-
dard as the intervention with the highest expected net benefit
(£9895), followed by varenicline low 1 NRT standard (£9759).
Discussion
Our results show that, in the base case, when the analysis is
limited to UK-licensed interventions (and neuropsychiatric events
included), varenicline standard is most cost-effective at any will-
ingness to pay value above £15 665. When all interventions are
included, e-cigarette low is most cost-effective at any willingness
to pay value above £56. At a willingness to pay of £20 000,
e-cigarette low, varenicline standard 1 bupropion standard, and
varenicline standard 1 NRT standard were found to be most cost-
effective. The results have also shown that including the safety
outcomes of depression and self-harm makes a difference. When
these are not accounted for, varenicline standard 1 NRT standard
is most cost-effective at any willingness-to-pay value above £1302.
VoI analyses have indicated that a trial comparing e-cigarettes to
an active comparator such as varenicline standard 1 bupropion
standard or NRT standard is likely to be a cost-effective invest-
ment. Although more research is needed, these results suggest
that decision and policymakers should consider licensing of
combination interventions and e-cigarettes. The prescription of
these interventions on the NHS could lead to better outcomes at
reduced costs.
No previous CEA was identified that compared a similar range
of interventions, including standard licensed interventions, com-
bination therapies, and e-cigarettes, or incorporating safety out-
comes. A recent systematic review of CEAs39 identified 4 studies
published in the past 10 years which compared varenicline,
bupropion, or NRT to each other or to standard of care.20,26,57,58 All
but one of these studies58 also used the BENESCO model but none
adjusted to account for safety outcomes. In agreement with our
findings, the studies consistently found varenicline to be the most
cost-effective intervention. Our model differs from the previous
models by including adverse events for depression and self-harm.
We explored the impact of excluding these adverse events in a
sensitivity analysis. We found that when considering both
licensed and unlicensed interventions the combination of vare-
nicline and NRT was most cost-effective when adverse events
were not included, but that e-cigarettes low and the combination
of varenicline standard and bupropion standard were more cost-
effective when adverse events were included.
One previous study was identified which compared the cost-
effectiveness of e-cigarettes to NRT in stop smoking services in
England.59 Similar to our study where an ICER of £56 was calcu-
lated for e-cigarette low compared with NRT low, this study found
an ICER of £65 per QALY gained by using e-cigarettes in compar-
ison with NRT. However, to our knowledge, our study is the first to
assess the cost-effectiveness of e-cigarettes compared with all
other interventions in the United Kingdom.
There were several data limitations including a lack of
comparative evidence on subsequent quit attempts in these in-
terventions. The model assumes that, after a failed first attempt,
smokers remain so until death, when in reality people often make
several quit attempts before they are successful. We would expect
our findings to be robust to this however as long as the likelihood
Table 3. Expected total costs, expected total utilities, ICERs and expected net benefit at a £20 000 willingness-to-pay threshold.
Intervention Total costs Total QALYs ICER ENB (95% CI) (£) Median rank (IQR)
NRT low £10 259 10.934 0 13 (12-14)
E-cigarette low £10 279 11.290 £56 7085 (6964, 7205) 3 (1-6)
Bupropion low £10 283 11.038 Dominated 2056 (2010, 2102) 11 (9-12)
NRT STD £10 292 11.119 Dominated 3663 (3617, 3710) 6 (5-8)
Bupropion std £10 304 11.033 Dominated 1937 (1902, 1971) 11 (10-12)
NRT high £10 309 11.092 Dominated 3092 (3053, 3131) 8 (7-10)
E-cigarette high £10 319 11.189 Dominated 5036 (4967, 5104) 5 (3-7)
Bupropion std 1 NRT high £10 346 11.128 Dominated 3786 (3710, 3862) 7 (4-11)
Varenicline STD £10 413 11.127 Dominated 3697 (3659, 3734) 7 (6-8)
Varenicline STD 1 bupropion STD £10 437 11.281 Dominated 6756 (6669, 6843) 3 (2-5)
Varenicline low £10 440 10.959 Dominated 308 (211, 405) 12 (10-14)
Varenicline STD 1 NRT high £10 467 11.117 Dominated 3440 (3370, 3509) 8 (5-11)
Varenicline low 1 NRT STD £10 587 11.273 Dominated 6454 (6313, 6595) 3 (2-8)
Varenicline STD 1 NRT STD £10 587 11.280 Dominated 6591 (6472, 6710) 3 (2-6)
CI indicates confidence interval; ENB, expected net benefit; EVPPI indicates expected value of partially perfect information; ICER, incremental cost-effectiveness ratio;
IQR, interquartile range; NRT, nicotine replacement therapy; QALY, quality adjusted life years; STD, xxxx.
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of a successful subsequent quit attempt does not depend on the
initial intervention.
Another data limitation is the assumption that the risk ratios of
developing or dying from smoking-related diseases in current
smokers and former smokers compared to nonsmokers are equal
to the risk ratios of having smoking related-diseases. We consid-
ered this reasonable given that no alternative sources of infor-
mation on relative incidence or mortality within the specified age
and sex categories could be identified. Longitudinal studies
measuring these outcomes for the different smoker categories
would be useful to inform future models.
This distribution of the cohort across sex and age categories at
the start of the model was designed to reflect the distribution of
smokers in the United Kingdom. One issue is that this is not
necessarily the same as the distribution of smokers making a quit
attempt. Another is that data availability meant that this cohort
needed to be grouped into broad age categories (18-34, 35-64,
.65 years old) which have been assigned the same prevalence,
incidence, and probability of mortality from diseases within each
category. It is likely, therefore, that greater variation exists within
these categories than is being accounted for. A study measuring
patient characteristics of those seeking intervention to make a
quit attempt would also be useful to update the model to better
reflect the population of interest.
With no medically licensed e-cigarettes available in the United
Kingdom it is difficult to estimate a prescribing cost if they were to
be prescribed on the NHS. The best evidence we could find on this
was from the Irish Health Information Quality Authority HTA,60
which estimated a 12-week supply of e-cigarettes as V93.80.
Current high-street/internet prices may be considerably lower
than this; however, it is unclear whether the NHS would be able to
access these lower prices. If a lower price could be accessed this
could only have the impact of increasing the cost-effectiveness of
e-cigarettes compared to the other interventions.
Despite the large number of studies included in the NMAs (161
in the NMA on sustained abstinence and 73 in the NMA on
MANEs), comparisons between active interventions were almost
exclusively informed by indirect evidence. This resulted in
imprecisely estimated effects and wide confidence intervals in
some cases. In our model we included depression and self-harm as
adverse events. The label for varenicline however mentions
depressed mood. We did not find sufficient data to include this in
the model, and so instead included depression, which was re-
ported in the RCTs and cohort studies identified in our searches. In
addition, as no data were available, assumptions had to made
about the relative effectiveness of several interventions for the
outcomes of depression and self-harm. More studies comparing
the impact of different doses and combinations of these in-
terventions on abstinence and psychological outcomes would be
useful to inform the model. In particular, more trials comparing
e-cigarettes with active interventions are needed to assess their
short- and long-term safety.
Conclusions
This study used up to date information to give an estimate of
the most cost-effective intervention for smoking cessation in the
United Kingdom. This analysis has shown that in the base case,
among licensed interventions, varenicline standard or NRT stan-
dard appear to be most cost-effective. When all licensed and un-
licensed comparators are included, e-cigarette low, varenicline
standard 1 bupropion standard, or varenicline standard 1 NRT
standard appear to be most cost-effective. When the impact of the
safety outcomes of depression and self-harm is excluded, vareni-
cline standard 1 NRT standard and varenicline low 1 NRT
standard are the most cost-effective interventions.
We recommend that researchers continue to investigate the
use of e-cigarettes for smoking cessation, particularly with respect
to long-term effectiveness and safety outcomes, preferably in
studies with active interventions as comparators. Our VoI analysis
suggested that a large adequately powered and well-conducted
trial comparing E-cigarettes to an active comparator such as
Table 4. Expected total costs, expected total utilities, ICERs and expected net benefit at a £20 000 willingness-to-pay threshold based on
abstinence alone.
Intervention Total costs Total QALYs ICER ENB Median rank (IQR)
Bupropion low £10 219 11.135 3159 (3114, 3204) 11 (9-12)
NRT low £10 231 10.977 Dominated 0 14 (14-14)
NRT high £10 238 11.198 Extendedly dominated 4400 (4365, 4434) 7 (6-8)
Bupropion STD £10 240 11.130 Dominated 3041 (3008, 3073) 11 (10-12)
E-cigarette high £10 248 11.295 Extendedly dominated 6335 (6269, 6401) 4 (3-6)
E-cigarette low £10 250 11.332 £159 7072 (6958, 7187) 4 (2-8)
NRT STD £10 264 11.162 Dominated 3657 (3628, 3686) 9 (8-10)
Bupropion std 1 NRT high £10 319 11.168 Dominated 3721 (3647, 3794) 10 (6-13)
Varenicline low £10 320 11.138 Dominated 3120 (3076, 3164) 11 (9-12)
Varenicline STD £10 327 11.254 Dominated 5434 (5399, 5469) 5 (4-6)
Varenicline STD 1 NRT high £10 402 11.214 Dominated 4556 (4492, 4619) 10 (6-13)
Varenicline STD 1 bupropion STD £10 415 11.314 Dominated 6558 (6475, 6642) 4 (3-7)
Varenicline low 1 NRT STD £10 446 11.476 Extendedly dominated 9759 (9636, 9882) 2 (1-4)
Varenicline STD 1 NRT STD £10 447 11.483 £1,302 9895 (9799, 9991) 2 (1-3)
ENB indicates expected net benefit; ICER, Incremental cost-effectiveness ratios; IQR, interquartile range; NRT, nicotine replacement therapy; QALY, quality adjusted life
years; STD, standard.
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varenicline standard 1 bupropion standard or NRT standard is
likely to be a cost-effective use of resources.
Supplemental Material
Supplementary data associated with this article can be found in the
online version at https://doi.org/10.1016/j.jval.2020.12.012.
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